SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 23, 2005
BioMed Realty Trust, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Maryland |
|
1-32261 |
|
20-1142292 |
(State or Other Jurisdiction of
Incorporation)
|
|
(Commission File No.)
|
|
(I.R.S. Employer
Identification No.) |
17140 Bernardo Center Drive, Suite 222
San Diego, California 92128
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (858) 485-9840
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
TABLE OF CONTENTS
Item 1.01 Entry into a Material Definitive Agreement.
On September 23, 2005, BioMed Realty Trust, Inc., through its subsidiary, BMR-675 West Kendall
Street LLC, entered into a Sixth Amendment to Lease with Vertex Pharmaceuticals Incorporated with
respect to the company’s Kendall Square A property. Under the amendment, BioMed agreed to extend
the completion dates for certain tenant improvements being performed by Vertex. The foregoing
description of the amendment does not purport to be complete and is qualified in its entirety by
reference to the complete text of the amendment, which is filed as an exhibit to this report and
incorporated herein by reference.
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers.
On September 28, 2005, BioMed’s Board of Directors appointed Karen A. Sztraicher as the
company’s Principal Accounting Officer, effective immediately. Ms. Sztraicher, 42, joined BioMed
in 2004 as its Senior Controller and currently serves as its Vice President – Chief Accounting
Officer. Prior to joining BioMed, she served as Chief Financial Officer of GMS Realty, LLC, a
private real estate company focused on acquiring, developing and operating retail properties in the
western United States, from 1999 to 2004, and Vice President Accounting of GMS Realty from 1997 to
1999. Ms. Sztraicher became a certified public accountant in 1988.
Item 9.01 Financial Statements and Exhibits.
(c) The following exhibits are filed herewith:
| |
|
|
| Exhibit |
|
|
| Number |
|
Description of Exhibit |
10.1
|
|
Sixth Amendment to Lease, dated as of September 23, 2005, by and
between BMR-675 West Kendall Street LLC, as successor to Kendall
Square, LLC, and Vertex Pharmaceuticals Incorporated. |
2